Volume 6.21 | Jun 5

Mammary Cell News 6.21 June 5, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
A Community Effort to Assess and Improve Drug Sensitivity Prediction Algorithms
The authors focused on predicting drug response based on a cohort of genomic, epigenomic and proteomic profiling data sets measured in human breast cancer cell lines. Through a collaborative effort between the National Cancer Institute and the Dialogue on Reverse Engineering Assessment and Methods project, they analyzed a total of 44 drug sensitivity prediction algorithms. [Nat Biotechnol] Abstract | Press Release
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

An Epigenomic Approach to Therapy for Tamoxifen-Resistant Breast Cancer
In an effort to identify novel regulators of estrogen receptor alpha (ERα) signaling, through a small-scale siRNA screen against histone methyl modifiers, investigators found WHSC1, a histone H3K36 methyltransferase, as a positive regulator of ERα signaling in breast cancer cells. [Cell Res] Full Article

Targeting RPL39 and MLF2 Reduces Tumor Initiation and Metastasis in Breast Cancer by Inhibiting Nitric Oxide Synthase Signaling
Selective shRNA knockdown identified ribosomal protein L39 (RPL39) and myeloid leukemia factor 2 (MLF2) as the top candidates that affect breast cancer stem cell (BCSC) self-renewal. Knockdown of RPL39 and MLF2 by specific siRNA nanoparticles in patient-derived and human cancer xenografts reduced tumor volume and lung metastases with a concomitant decrease in BCSCs. [Proc Natl Acad Sci USA] Abstract

STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer
Researchers constructed a series of lentiviral fluorescent reporters that enabled flow cytometric enrichment of cells differing in STAT3-mediated transcriptional activity, as well as in vivo/in situ localization of STAT3 responsive cells. [Stem Cells] Abstract

Aldehyde Dehydrogenase and Estrogen Receptor Define a Hierarchy of Cellular Differentiation in the Normal Human Mammary Epithelium
Investigators used fluorescence activated cell sorting of primary human mammary epithelial cells along with in vitro and in vivo functional assays to examine the hierarchical relationship between cells with aldehyde dehydrogenase enzymatic activity and estrogen receptor positive cells in the normal human breast epithelium. [Breast Cancer Res] Abstract | Full Article

Chromatinized PKC-θ Directly Regulates Inducible Genes in Epithelial to Mesenchymal Transition and Breast Cancer Stem Cells
Scientists showed that crosstalk between signaling kinases and chromatin is critical for eliciting inducible transcriptional programs that drive mesenchymal differentiation and cancer stem cell formation, providing novel mechanisms to target using epigenetic therapy in breast cancer. [Mol Cell Biol] Abstract

Estrogen Promotes Stemness and Invasiveness of ER-Positive Breast Cancer Cells through Gli1 Activation
Considering that Gli1, part of the Sonic hedgehog developmental pathway, has been shown to mediate breast cancer (BC) stem cells (CSCs), researchers investigated whether estrogen and Gli1 could promote CSCs and epithelial-mesenchymal transition in estrogen receptor positive (ER+) BC cell lines. [Mol Cancer]
Abstract | Full Article

Growth Hormone Is Secreted by Normal Breast Epithelium upon Progesterone Stimulation and Increases Proliferation of Stem/Progenitor Cells
Using in vitro and in vivo experimental systems and in situ analysis, scientists showed that growth hormone is secreted locally by normal human mammary epithelial cells upon progesterone stimulation. [Stem Cell Rep]
Full Article | Graphical Abstract

CLINICAL RESEARCH

Distant Invasive Breast Cancer Recurrence Risk in Human Epidermal Growth Factor Receptor 2-Positive T1a and T1b Node-Negative Localized Breast Cancer Diagnosed from 2000 to 2006: A Cohort from an Integrated Health Care Delivery System
Investigators determined the invasive recurrence risk among patients with small, node-negative human epidermal growth factor receptor 2-positive breast cancer. [J Clin Oncol] Abstract | Press Release

A Multi-Institutional Study on the Association between BRCA1/BRCA2 Mutational Status and Triple-Negative Breast Cancer in Familial Breast Cancer Patients
Researchers studied 221 familial breast and/or ovarian cancer patients from 37 hospitals using a comprehensive approach to identify large genomic rearrangements as well as sequence variants, and investigated the association between BRCA1/2 mutational status and triple-negative breast cancer. [Breast Cancer Res Treat] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
Non-Viral Nanocarriers for siRNA Delivery in Breast Cancer
Non-viral nanocarriers have attracted attention based on their potential for targeted delivery of small interfering RNA (siRNA) and efficient gene silencing without toxicity. Researchers review promising, non-viral delivery strategies employing liposomes, nanoparticles and inorganic materials in breast cancer. [J Control Release] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
SCIENCE NEWS
Potential Breast Cancer Drug Performs Well in Early Clinical Trials
A drug previously studied to improve chemotherapy may be effective in treating patients with cancers related to the BRCA 1 or 2 genetic mutations, as well as patients with BRCA-like breast cancers. [Press release from the University of Pittsburgh discussing research presented at the 50th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago] Press Release

ALTTO Test of Dual HER2 Blockade Finds Single Agent – Trastuzumab – Remains Gold Standard
In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report. [Press release from the Mayo Clinic discussing research presented at the 50th Annual Meeting American Society of Clinical Oncology (ASCO), Chicago] Press Release | Video

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
 
INDUSTRY NEWS
Immune Design Announces Treatment of First Patient in Phase I Clinical Trial of LV305 Immuno-Oncology Agent
Immune Design announced treatment of the first patient in a Phase I clinical trial of LV305, an immuno-oncology investigational agent from the company’s DCVexTM lentiviral vector platform. The Phase I open label, multi-center trial is designed to evaluate the safety, tolerability and immunogenicity of LV305 in patients with locally advanced, relapsed, or metastatic breast cancer, melanoma, non-small cell lung cancer, ovarian cancer or sarcoma. [Immune Design] Press Release

Advanced Cancer Therapeutics Enters Phase I Human Clinical Trials with First-in-Class Anti-Cancer Drug Candidate
Advanced Cancer Therapeutics announced that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials. The U.S. Food and Drug Administration approved Phase I dose escalation study is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as melanoma, lung, colon, breast and pancreatic cancer. [Advanced Cancer Therapeutics] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2014 Best of American Society of Clinical Oncology (ASCO) Boston Meeting
August 8-9, 2014
Boston, United States

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Scholar – Cancer and RNA Research (Northwestern University)

PhD Scholarship – Breast Cancer (Royal College of Surgeons in Ireland)

Postdoctoral Research Associates – Pattern Formation during Branching Morphogenesis of the Mammary Gland (Princeton University)

Postdoctoral Positions – Breast Cancer, Mouse Models, Tumor Microenvironment (National Cancer Institute)

Postdoctoral Training Fellow – Breast Cancer Functional Genomics (Institute of Cancer Research)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us